NCT06897657View on ClinicalTrials.gov

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

CompletedOBSERVATIONAL
Enrollment

155

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

July 25, 2024

Study Completion Date

July 25, 2024

Conditions
Multiple Sclerosis, Relapsing-Remitting
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY